Partner Headlines - CPHD

  1. Stocks Fall For Fourth Day On Global Growth Worries

    IBD
  2. Major Indexes Extend Losses; Sucampo Bucks Weakness

    IBD
  3. Morning Market Losers

    Benzinga
  4. Stocks On Pace For Fourth Straight Gain; GoPro Gains

    IBD
  5. Stocks Hold On To Most Gains; Biotechs Quicken Their Pulse

    IBD
  6. Stocks Lower In Late Trading, But Utilities Rally

    IBD
  7. Craig-Hallum Upgrades Cepheid To Buy

    Benzinga
  8. Morning Market Gainers

    Benzinga
  9. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga
  10. Novartis, Verastem & Cepheid Making Biotech Headlines On Friday

    Benzinga
  11. Leading Medical Stock Cepheid Trying To Break Out

    IBD
  12. Benzinga's Top Upgrades

    Benzinga
  13. Bank of America Upgrades Cepheid To Buy

    Benzinga
  14. UPDATE: Citigroup Reiterates On Cepheid Following Positive Data

    Benzinga
  15. Top Medical Stocks: Cepheid Diagnostics Sales Strong

    IBD
  16. Cepheid Receives FDA Clearance For Xpert Norovirus, The First ...

    Benzinga
  17. CEPHEID

    IBD
  18. Cepheid Receives FDA Clearance For Xpert Flu/RSV XC

    Benzinga
  19. Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

    Benzinga
  20. Several Sectors Emerge As Leaders Of New Market Uptrend

    IBD
  21. Stocks Fight Back To Finish Mixed

    IBD
  22. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD
  23. Cepheid Explores Test For Ebola Disease; Q3 Beats

    IBD
  24. CEPHEID

    IBD
  25. Cepheid Extends Reach Of Direct US Commercial Operations

    Benzinga
  26. UPDATE: ISI Group Upgrades Cepheid

    Benzinga
  27. CEPHEID

    IBD
  28. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  29. Alexion Takes Off On Outlook

    IBD
  30. Three Medical Tech Names To Watch In Healthcare Space

    IBD
  31. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD
  32. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market ...

    Benzinga
  33. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  34. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  35. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining ...

    Benzinga
  36. Benzinga's Top Downgrades

    Benzinga
  37. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga
  38. Benzinga's Top Downgrades

    Benzinga
  39. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' ...

    Benzinga
  40. Cepheid Announces Board of Directors Changes

    Benzinga
  41. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate ...

    Benzinga
  42. Medtech Stocks Moving As Conference Makes Waves

    IBD
  43. Medtech Stocks Moving As Conference Makes Waves

    IBD
  44. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ...

    Benzinga
  45. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga
  46. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on ...

    Benzinga
  47. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga
  48. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga
  49. US Stock Futures Down Ahead Of Economic Data

    Benzinga
  50. Stocks To Watch For December 28, 2012

    Benzinga
  51. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga
  52. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, ...

    Benzinga
  53. Look At That Base: If You Can't Name It, Don't Buy It

    IBD
  54. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of ...

    Benzinga
  55. Benzinga's Top Downgrades

    Benzinga
  56. Benzinga's Top Upgrades

    Benzinga
  57. CEPHEID Reports Operating Results (10-Q)

    GuruFocus
  58. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst ...

    Benzinga
  59. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 ...

    Benzinga
  60. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga
  61. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst ...

    Benzinga
  62. Benzinga Mid-Afternoon Market Update

    Benzinga
  63. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard ...

    MarketIntelligenceCenter
  64. Benzinga Mid-Day Market Update

    Benzinga
  65. Mid-Morning Market Update

    Benzinga
  66. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative ...

    Benzinga
  67. Benzinga's Top Initiations

    Benzinga
  68. A Peek Into The Market Before The Trading Starts

    Benzinga
  69. UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

    Benzinga
  70. Benzinga's Top Initiations

    Benzinga
  71. Technology Sector Wrap

    FoxBusiness
  72. Technology Sector Wrap

    FoxBusiness
  73. Technology Sector Wrap

    FoxBusiness
  74. Analyst Downgrades: Cepheid, Intuitive Surgical, and Travelzoo

    SchaeffersResearch
  75. Cepheid Down 20% on Weak Guidance

    Benzinga
  76. CEPHEID (CPHD) CEO John L Bishop sells 40,201 Shares

    GuruFocus
  77. CEPHEID (CPHD) CEO John L Bishop sells 25,000 Shares

    GuruFocus
  78. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 17,437 Shares

    GuruFocus
  79. A Peek Into The Market Before The Trading Starts

    Benzinga
  80. UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic ...

    Benzinga
  81. Benzinga's Top Downgrades With Color for May 14, 2012

    Benzinga
  82. UPDATE: GARP Research & Securities Downgrades Cepheid to Neutral; ...

    Benzinga
  83. Cepheid Earnings Miss Estimates; Stock Plummets

    IBD
  84. Cepheid Q1 Estimates Soft, But Outlook For Year Good

    IBD
  85. Zoll Deal, Intutive Surgical Lift Medical Equipment

    IBD
  86. Cepheid Stock Price Rises on Strong 2012 Sales Outlook

    IBD
  87. CEPHEID Reports Operating Results (10-K)

    GuruFocus
  88. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 62,062 Shares

    GuruFocus
  89. CEPHEID (CPHD) CEO John L Bishop sells 6,887 Shares

    GuruFocus
  90. CEPHEID (CPHD) Executive VP, COO Humberto Reyes sells 133,957 ...

    GuruFocus
  91. Stocks Finish Week Split; Nasdaq, S&P 500 Higher

    IBD
  92. Stocks Stay Mixed; Under Armour Clears 50-Day

    IBD
  93. RBC Capital Upgrades Cepheid to Outperform

    Benzinga
  94. UPDATE: Credit Suisse Initiates Outperform, $40 Target on Cepheid

    Benzinga
  95. Analogic Earnings Preview: EPS Expected to Double

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!